Equity Overview
Price & Market Data
Price: $0.0114
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $1,703,118
Daily Volume: 0
Performance Metrics
1 Week: 0.88%
1 Month: 28.09%
3 Months: -49.11%
6 Months: -50.86%
1 Year: -56.98%
YTD: -59.29%
Company Details
Employees: 7
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.